We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 629

Including Functional Claim Language Helped Save Pozen’s VIMOVO Patents
  • Jones Day
  • USA
  • March 21 2017

On February 28, 2017, the PTAB held that the petitioner Lupin had not shown that the challenged claims in two of Pozen’s patents were invalid


Food, Dietary Supplement & Cosmetics Regulatory Update Vol. IV, Issue 2
  • Jones Day
  • European Union, USA
  • March 17 2017

President Trump to Nominate Scott Gottlieb as FDA Commissioner According to a White House statement, President Trump


Global Privacy & Cybersecurity Update Vol. 13 - March 2017
  • Jones Day
  • Asia-Pacific, Australia, Canada, Central & South America, China, European Union, Hong Kong, Japan, Singapore, USA
  • March 10 2017

On December 28, 2016, the New York Department of Financial Services ("DFS") released a revised version of a proposed regulation that would require


Secondary Considerations Unsuccessful Once Again
  • Jones Day
  • USA
  • March 1 2017

As reported in our February 1, 2017 post, patent owners have had a difficult time convincing the PTAB that secondary considerations are sufficient to


PTAB Rejects Flawed Inherency Argument Against Drug Composition Patent
  • Jones Day
  • USA
  • February 24 2017

On February 3, 2017, the PTAB denied a petition by Amneal Pharmaceuticals LLC ("Amneal") to institute an inter partes review of Hospira Inc.'s patent


Food, Dietary Supplement & Cosmetics Regulatory Update Vol. IV, Issue 1
  • Jones Day
  • European Union, United Kingdom, USA
  • February 16 2017

On January 20, 2017, the Trump Administration issued a memorandum "for the Heads of Executive Departments and Agencies" requesting the "regulatory


PTAB Institutes Separate IPR Proceedings Filed by Codefendants, Finding that the Later IPR Proceeding Was Not Barred by 35 U.S.C. 325(d)
  • Jones Day
  • USA
  • January 30 2017

On January 19, 2017, the PTAB instituted inter partes review of U.S. Patent No. 8,822,438 (“the ’438 patent”) filed by Wockhardt Bio AG (“Wockhardt”


PTAB Upholds Sloan Kettering’s Cancer Immunotherapy Patent
  • Jones Day
  • USA
  • January 26 2017

By Galina Steinberg-Tatman, Ph.D. And Cary Miller, Ph.D. On December 16, 2016, the PTAB issued a Final Written Decision in case IPR2015-01719


Regulatory Developments Life Sciences Companies Should Expect in the New Presidential Administration
  • Jones Day
  • USA
  • January 20 2017

2017 and beyond promises to be a time for continued evolution and uncertainty for life sciences companies doing business in the United States. In


21st Century Cures ActFebruary 11, 2017, Deadline for Company Disclosure of Expanded Access Programs
  • Jones Day
  • USA
  • January 17 2017

The landmark 21st Century Cures Act1 ("Cures Act"), which was signed into law by President Obama and became effective on December 13, 2016